AKBA Akebia Therapeutics Inc.

5.6
+0.2  (+4%)
Previous Close 5.4
Open 5.45
Price To Book 1.16
Market Cap 660030515
Shares 117,862,592
Volume 1,022,638
Short Ratio
Av. Daily Volume 1,430,161

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated in 2019.
Vadadustat - TRILO2GY
Three-times-weekly dosing regimen for vadadustat
Phase 2 trial data due 2019.
Vadadustat - FO2RWARD
Renal anemia
Approved Sept 5, 2014.
Auryxia
Hyperphosphatemia
Phase 3 data due 2Q 2020.
Vadadustat - INNO2VATE
Anemia related to chronic kidney disease who are undergoing dialysis (DD-CKD)
Phase 3 data due mid-2020.
Vadadustat - PRO2TECT
Non-dialysis patients with anemia related to CKD (NDD-CKD)
sNDA FDA Approval announced November 7, 2017.
Auryxia
Iron deficiency anemia in non-dialysis dependent CKD patients

Latest News

  1. Edited Transcript of AKBA earnings conference call or presentation 9-May-19 1:00pm GMT
  2. Akebia Therapeutics, Inc. (AKBA) Q1 2019 Earnings Call Transcript
  3. Here’s What Hedge Funds Think About Akebia Therapeutics Inc (AKBA)
  4. Akebia Therapeutics: 1Q Earnings Snapshot
  5. Akebia Therapeutics Reports First Quarter 2019 Financial Results; Announces Full Enrollment of Phase 3 INNO2VATE Studies and Announces Key Executive Appointments
  6. Seth Klarman Keeps Buying This Biotech Stock
  7. Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  8. Will Akebia Therapeutics (AKBA) Report Negative Earnings Next Week? What You Should Know
  9. Akebia and Otsuka Pharmaceutical Development & Commercialization Inc (OPDC) Announce Presentation of Four Posters at the NKF 2019 Spring Clinical Meetings
  10. Akebia Therapeutics to Report First Quarter 2019 Financial Results
  11. Akebia Expands Vadadustat Licensing Deal With Vifor Pharma
  12. Vifor Pharma and Akebia Therapeutics Announce Expansion of License Agreement
  13. Vifor Pharma and Akebia Therapeutics Announce Expansion of Licence Agreement
  14. Akebia Therapeutics to Present at the 18th Annual Needham Healthcare Conference
  15. Medison to Nominate Six Highly Qualified Directors for Knight Therapeutics' Board to Strengthen Oversight and Drive Value Creation for All Shareholders
  16. Consolidated Research: 2019 Summary Expectations for ADT, HudBay Minerals, Whirlpool, Akebia Therapeutics, Nevro, and MicroStrategy — Fundamental Analysis, Key Performance Indications
  17. Akebia Therapeutics Inc (AKBA) Files 10-K for the Fiscal Year Ended on December 31, 2018
  18. Edited Transcript of AKBA earnings conference call or presentation 18-Mar-19 8:30pm GMT